Feds Introducing BigPharma to FCPA – Law Blog – WSJ

Lanny Breuer, the head of the Justice Department’s Criminal Division, told drug-company executives last year that investigating foreign bribery in the industry would be one of his priorities over the next several years.

Looks like he’s staying true to his word.

On Tuesday, the WSJ’s Michael Rothfeld reports that federal investigators are looking at ways that drug makers could be paying bribes overseas to boost sales and speed approvals.

Big companies—including Merck, AstraZeneca, Bristol-Myers Squibb and GlaxoSmithKline —in recent months have disclosed they are being investigated for possible violations of the Foreign Corrupt Practices Act, the now ubiquitous 1977 law that makes it illegal for companies whose stock is traded in the U.S. to bribe government officials in other countries to get business.

The companies said they are cooperating with the government, with several adding that the investigation is industry-wide and broader than their companies specifically. So far, none of the companies has been accused of wrongdoing, and the investigation ultimately may not result in charges.

The investigation is targeting transactions in Brazil, China, Germany, Italy, Poland, Russia and Saudi Arabia, people familiar with the matter said.

via Feds Introducing BigPharma to FCPA – Law Blog – WSJ.

UK drug firms put under microscope over ‘bribery’ – Business News, Business – The Independent

The world’s largest pharmaceutical companies are facing a corruption investigation in the United States over claims that the hospitality lavished on those who prescribe their treatments could constitute bribery.

Britain’s two biggest drug groups, GlaxoSmithKline (GSK) and AstraZeneca, are among those facing the investigation, which is being carried out jointly by the Department of Justice (DoJ) and Securities and Exchange Commission (SEC). The investigation is thought to centre around allegations that drugs companies might have contravened the Foreign Corrupt Practices Act (FCPA), which limits their ability to spend on such “soft’ inducements” as hospitality, charitable donations and other non-business activities.

The list of the companies under investigation contains many of the global pharma industry’s biggest names: Pfizer, Bristol-Myers Squibb and Eli Lilly are among those under the spotlight.

The DoJ is looking into claims that the industry has for years ignored obligations under anti-bribery legislation, and that the situation is so stark, some of the hospitality extended to those that buy treatments could amount to bribery.

The probe is into activities outside the US. If found guilty, the industry could face fines totalling millions of dollars.

via UK drug firms put under microscope over ‘bribery’ – Business News, Business – The Independent.

More Attorneys Exploring Third-Party Litigation Funding | NY Law Journal

Ask Louis M. Solomon where his fees are coming from these days, and you will get a complicated answer.

Solomon, who joined Cadwalader, Wickersham & Taft earlier this year, counts corporations such as Bristol-Myers Squibb and PepsiCo as part of his book of business. Yet while companies like those still are generally paying his fees, lately the source of funds is not just his clients’ corporate war chests but money they received from investors looking to take stakes in the lawsuits he files for them.

Solomon, 54, is among a handful of corporate litigators handling commercial disputes with outside, third-party litigation funding. Two litigation funds have in the last three years launched initial public offerings, and both are on the lookout for U.S. litigants who would allow them to finance their cases in return for a portion of any settlement or judgment.

Juridica Investments Limited, which launched in 2007, last month reported that through March it had committed almost $123 million to 15 investments in 22 cases, one of which is in New York, according to a spokesman. Burford Capital Ltd., which went public in October, has so far invested $40 million across 10 cases, many of them international arbitrations.

But the practice of allowing outside investors into lawsuits is not without its critics. The U.S. Chamber of Commerce in October called for the prohibition of third-party litigation financing at all levels.

Selvyn Seidel, a former Latham & Watkins partner who is chairman of the investment advisor side of Burford, said the concern is understandable given the relative newness of the investment funds in the United States.

“The industry’s biggest enemy is unawareness,” he said. “And most of the lawyers in the U.S. are unaware of it.”

Third-party litigation funding is a relatively recent phenomenon in the United States, after establishing itself in Australia, then later in the United Kingdom. Until recently, in the United States it tended to focus on consumer disputes like personal injury claims, with advances of $1,750 to $4,500 in exchange for a percentage of the recovery, according to a Juridica-funded report by RAND Corporation released last month.

The newer phenomenon has been the emergence of investors like Juridica and Burford, which finance commercial claims brought by companies against other companies. While not alone in the field — Credit Suisse has a unit that invests in litigation — Juridica and Burford are two of the largest funds dedicated solely to litigation finance. Both are publicly traded on the Alternative Investment Market in the United Kingdom, where investors are likely more familiar with these types of funds.

Burford raised about $130 million in an October IPO and is looking to invest in commercial disputes. It plans to make average investments exceeding $3 million, and expects to have its capital fully committed by October 2011. Seidel declined to provide details on a suit in which Burford has invested.

via Law.com – More Attorneys Exploring Third-Party Litigation Funding.

More Attorneys Exploring Third-Party Litigation Funding | NY Law Journal

Ask Louis M. Solomon where his fees are coming from these days, and you will get a complicated answer.

Solomon, who joined Cadwalader, Wickersham & Taft earlier this year, counts corporations such as Bristol-Myers Squibb and PepsiCo as part of his book of business. Yet while companies like those still are generally paying his fees, lately the source of funds is not just his clients' corporate war chests but money they received from investors looking to take stakes in the lawsuits he files for them.

Solomon, 54, is among a handful of corporate litigators handling commercial disputes with outside, third-party litigation funding. Two litigation funds have in the last three years launched initial public offerings, and both are on the lookout for U.S. litigants who would allow them to finance their cases in return for a portion of any settlement or judgment.

Juridica Investments Limited, which launched in 2007, last month reported that through March it had committed almost $123 million to 15 investments in 22 cases, one of which is in New York, according to a spokesman. Burford Capital Ltd., which went public in October, has so far invested $40 million across 10 cases, many of them international arbitrations.

But the practice of allowing outside investors into lawsuits is not without its critics. The U.S. Chamber of Commerce in October called for the prohibition of third-party litigation financing at all levels.

Selvyn Seidel, a former Latham & Watkins partner who is chairman of the investment advisor side of Burford, said the concern is understandable given the relative newness of the investment funds in the United States.

“The industry’s biggest enemy is unawareness,” he said. “And most of the lawyers in the U.S. are unaware of it.”

Third-party litigation funding is a relatively recent phenomenon in the United States, after establishing itself in Australia, then later in the United Kingdom. Until recently, in the United States it tended to focus on consumer disputes like personal injury claims, with advances of $1,750 to $4,500 in exchange for a percentage of the recovery, according to a Juridica-funded report by RAND Corporation released last month.

The newer phenomenon has been the emergence of investors like Juridica and Burford, which finance commercial claims brought by companies against other companies. While not alone in the field — Credit Suisse has a unit that invests in litigation — Juridica and Burford are two of the largest funds dedicated solely to litigation finance. Both are publicly traded on the Alternative Investment Market in the United Kingdom, where investors are likely more familiar with these types of funds.

Burford raised about $130 million in an October IPO and is looking to invest in commercial disputes. It plans to make average investments exceeding $3 million, and expects to have its capital fully committed by October 2011. Seidel declined to provide details on a suit in which Burford has invested.

via Law.com – More Attorneys Exploring Third-Party Litigation Funding.